HK1162302A1 - Elastase for opening obstructed biological conduits - Google Patents

Elastase for opening obstructed biological conduits

Info

Publication number
HK1162302A1
HK1162302A1 HK12102287.4A HK12102287A HK1162302A1 HK 1162302 A1 HK1162302 A1 HK 1162302A1 HK 12102287 A HK12102287 A HK 12102287A HK 1162302 A1 HK1162302 A1 HK 1162302A1
Authority
HK
Hong Kong
Prior art keywords
conduit
obstruction
elastase
enzyme
extracellular matrix
Prior art date
Application number
HK12102287.4A
Other languages
English (en)
Chinese (zh)
Inventor
Nicholas F Franano
Original Assignee
Proteon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Therapeutics Inc filed Critical Proteon Therapeutics Inc
Publication of HK1162302A1 publication Critical patent/HK1162302A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Processing Of Meat And Fish (AREA)
HK12102287.4A 1999-09-24 2012-03-07 Elastase for opening obstructed biological conduits HK1162302A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15593899P 1999-09-24 1999-09-24

Publications (1)

Publication Number Publication Date
HK1162302A1 true HK1162302A1 (en) 2012-08-31

Family

ID=22557384

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102287.4A HK1162302A1 (en) 1999-09-24 2012-03-07 Elastase for opening obstructed biological conduits

Country Status (12)

Country Link
EP (4) EP2332568A1 (fr)
JP (2) JP5763286B2 (fr)
AT (2) ATE511854T1 (fr)
AU (1) AU7612100A (fr)
CA (1) CA2385488C (fr)
CY (3) CY1106656T1 (fr)
DE (1) DE60034694T2 (fr)
DK (3) DK2363142T3 (fr)
ES (3) ES2364191T3 (fr)
HK (1) HK1162302A1 (fr)
PT (3) PT1923068E (fr)
WO (1) WO2001021574A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
JP2007525423A (ja) * 2003-02-20 2007-09-06 プロテオン セラピューティクス，インコーポレーテッド 生体導管の疾患を治療および予防するための方法
US20090196865A1 (en) * 2004-09-22 2009-08-06 Proteon Therapeutics, Inc. Methods for the treatment and prevention of diseases of biological conduits
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
NZ733709A (en) 2012-01-12 2022-10-28 Auxilium Int Holdings Inc Clostridium histolyticum enzymes and methods for the use thereof
WO2014066622A2 (fr) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Utilisation de collagénase dans le traitement du glaucome
CN110545722B (zh) 2017-03-01 2023-02-03 恩多风投有限公司 用于评估和治疗橘皮组织的装置和方法
JP7227918B2 (ja) 2017-03-28 2023-02-22 エンド ベンチャーズ リミテッド コラゲナーゼ産生の改良された方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489261A (en) * 1981-01-26 1996-02-06 Trustees Of Boston University Hydrogels capable of supporting cell growth
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4803294A (en) * 1987-10-29 1989-02-07 G. D. Searle & Co. Process and intermediates for the preparation of halogenated protease inhibitors
JPH0286777A (ja) * 1988-09-22 1990-03-27 Sankyo Co Ltd サル膵臓エラスターゼｉ
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
ATE121946T1 (de) * 1989-01-27 1995-05-15 Immunolytics Inc Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
NL8900943A (nl) * 1989-04-14 1990-11-01 Euro Biopharm Technology B V Protease inhibitor.
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5422261A (en) * 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
ES2281898T3 (es) * 1994-12-13 2007-10-01 Human Genome Sciences, Inc. Inhibidor tisular humano de metaloproteinasa-4.
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US5834449A (en) * 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors

Also Published As

Publication number Publication date
EP2363142B1 (fr) 2015-03-25
JP5793461B2 (ja) 2015-10-14
EP1923068A1 (fr) 2008-05-21
JP5763286B2 (ja) 2015-08-12
PT2363142E (pt) 2015-08-04
DK1220830T3 (da) 2007-07-16
JP2003523319A (ja) 2003-08-05
EP2363142B8 (fr) 2015-06-10
EP1220830B1 (fr) 2007-05-02
ES2534938T3 (es) 2015-04-30
PT1220830E (pt) 2007-06-11
WO2001021574A1 (fr) 2001-03-29
ES2284528T3 (es) 2007-11-16
WO2001021574A9 (fr) 2002-12-27
CY1112329T1 (el) 2015-12-09
EP1923068B1 (fr) 2011-06-08
ATE361095T1 (de) 2007-05-15
AU7612100A (en) 2001-04-24
EP2363142A9 (fr) 2011-10-19
CY1106656T1 (el) 2012-01-25
CY1117932T1 (el) 2017-05-17
DE60034694D1 (de) 2007-06-14
CA2385488C (fr) 2015-07-07
EP1220830A4 (fr) 2005-03-30
ES2364191T3 (es) 2011-08-26
ATE511854T1 (de) 2011-06-15
EP2332568A1 (fr) 2011-06-15
CA2385488A1 (fr) 2001-03-29
JP2012131830A (ja) 2012-07-12
DE60034694T2 (de) 2008-01-17
EP2363142A1 (fr) 2011-09-07
EP1220830A1 (fr) 2002-07-10
DK1923068T3 (da) 2011-06-27
DK2363142T3 (en) 2015-04-20
PT1923068E (pt) 2011-07-29

Similar Documents

Publication Publication Date Title
HK1162302A1 (en) Elastase for opening obstructed biological conduits
WO2000021461A3 (fr) Acheminement d'un conduit jusque dans une paroi du coeur pour mettre un vaisseau coronarien en communication avec une cavite du coeur et extraction de tissu du vaisseau ou de la paroi du coeur pour faciliter cette communication
WO2006083559A3 (fr) Systeme et methode de traitement de glaucome
SE9503562D0 (sv) Kateter, särskilt för peritonealdialys
WO2003051442A3 (fr) Catheter permettant l'administration endoluminale d'agents therapeutiques avec une reduction des pertes d'agent therapeutique
WO1998049972A3 (fr) Traitement differentiel de dispositifs de prothese
CY1107887T1 (el) Αρτηριοφλεβωδης επικοινωνια δια μεσω του μυοκαρδιου
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
HUT76023A (en) Method and device for combining at least two flow media
CA2075640A1 (fr) Procede et dispositif d'elimination des contaminants presents dans un fluide
FR2841137B1 (fr) Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
TR200402749T4 (tr) Bir diş kök kanalının yıkanması için yıkama kanulü.
AU2496199A (en) Copolymer compositions for oral delivery
WO2001034137A3 (fr) Combinaisons oncolytiques destinees au traitement du cancer
BR0215389A (pt) Agente preventivo ou terapêutico para distúrbio urinário, método para prevenir ou tratar distúrbio urinário, uso de um composto, composto, pró-droga, processo para preparar o composto, medicamento, e, método para triar um composto
WO2001034198A3 (fr) Combinaisons oncolytiques pour traitement des cancers
BR0313193A (pt) Sistema para a limpeza do intestino de um paciente, montagem de bocal; e método para a limpeza de um estoma
AU2001290468A1 (en) A device for catalytic treatment of a gas flow
CA2283129A1 (fr) Dispositif de separation de deux zones a ambiances differentes
GB2329326B (en) Apparatus for carrying a fluid flow
DE69309474D1 (de) Wasserspüleinrichtung
DE60038559D1 (de) Vorrichtung zum waschen des äusseren gehöhrganges
WO2001034134A3 (fr) Combinaisons oncolytiques pour traitement du cancer
FR2775184B1 (fr) Dispositif pour intervention chirurgicale destine a assurer une protection du patient contre les contaminations, notamment en chirurgie dentaire
EP1325974A3 (fr) Dispositif d'étanchéité pour équipements sous pression à travers lesquels le matériau à traiter est transporté

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190924